Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metlife (MET) Cash & Equivalents (2016 - 2025)

Metlife (MET) has 17 years of Cash & Equivalents data on record, last reported at $9.7 billion in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 19.83% year-over-year to $9.7 billion; the TTM value through Sep 2025 reached $9.7 billion, down 19.83%, while the annual FY2024 figure was $20.1 billion, 564.28% up from the prior year.
  • Cash & Equivalents reached $9.7 billion in Q3 2025 per MET's latest filing, down from $22.2 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $23.5 billion in Q1 2022 and bottomed at $1.3 billion in Q4 2022.
  • Average Cash & Equivalents over 5 years is $13.1 billion, with a median of $12.1 billion recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: plummeted 60.83% in 2023, then surged 564.28% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $2.0 billion in 2021, then plummeted by 34.22% to $1.3 billion in 2022, then soared by 134.19% to $3.0 billion in 2023, then soared by 564.28% to $20.1 billion in 2024, then tumbled by 51.66% to $9.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $9.7 billion in Q3 2025, $22.2 billion in Q2 2025, and $21.3 billion in Q1 2025.